Is this you? Create Your Porfile

T. Powles

Royal Free London NHS Foundation Trust

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where T. Powles is active.

Explore More

Publication

Featured researches published by T. Powles.

Journal of Clinical Oncology | 2016

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

Jonathan E. Rosenberg; Daniel P. Petrylak; Michiel S. van der Heijden; Andrea Necchi; Peter H. O'Donnell; Yohann Loriot; M. Retz; Jose Luis Perez-Gracia; Joaquim Bellmunt; Petros Grivas; Richard W. Joseph; Lawrence Fong; Edward E. Kadel; Zachary Boyd; Dorothee Nickles; Garrett Michael Frampton; Richard Bourgon; Priti Hegde; Sanjeev Mariathasan; T. Powles

Journal of Clinical Oncology | 2016

Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.

Arjun Vasant Balar; Matt D. Galsky; Yohann Loriot; Nancy A. Dawson; Andrea Necchi; Sandy Srinivas; Richard W. Joseph; Ulka N. Vaishampayan; Srikala S. Sridhar; David I. Quinn; Alexandra Drakaki; Ignacio Duran; Jonathan E. Rosenberg; T. Powles; Jean H. Hoffman-Censits; Na Cui; Sanjeev Mariathasan; Ann Christine Thastrom; Oyewale O. Abidoye; Dean F. Bajorin

Journal of Clinical Oncology | 2016

Association of PD-L2 expression in human tumors with atezolizumab activity.

Priti Hegde; Wei Zou; Marcin Kowanetz; Sanjeev Mariathasan; Luciana Molinero; Shirish M. Gadgeel; T. Powles; Michiel S. van der Heijden; Marcella Fasso; Carol O'Hear; Marcus Ballinger; Gregg Fine; Alan Sandler; Daniel S. Chen; F. Stephen Hodi

Annals of Oncology | 2016

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

Y. Loriot; Jonathan E. Rosenberg; T. Powles; Andrea Necchi; Syed A. Hussain; Rafael Morales; M. Retz; Günter Niegisch; Ignacio Duran; Christine Theodore; Jose Luis Perez-Gracia; E. Grande Pulido; Ann Christine Thastrom; B. Danner; Sanjeev Mariathasan; Oyewale O. Abidoye; M. Van Der Heijden

European Urology Supplements | 2017

Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

T. Powles; Joaquim Bellmunt; Daniel Castellano; P. O’Donnell; Petros Grivas; Jacqueline Vuky; Elizabeth R. Plimack; Noah M. Hahn; Arjun Vasant Balar; Lei Pang; Mary J. Savage; Rodolfo F. Perini; Stephen M. Keefe; Dean F. Bajorin; R. de Wit

Annals of Oncology | 2017

LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

Daniel P. Petrylak; Kim N. Chi; Alexandra Drakaki; C.N. Sternberg; R. de Wit; Hiroyuki Nishiyama; Evan Y. Yu; Daniel Castellano; Syed A. Hussain; I.J. Percent; Aude Flechon; Aristotle Bamias; M. Van Der Heijden; Nobuaki Matsubara; B. Alekseev; Richard A. Walgren; Oday Hamid; Annamaria Zimmermann; Katherine M Bell-McGuinn; T. Powles

Journal of Clinical Oncology | 2016

BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.

T. Powles; Elaine Kilgour; Richard Mather; Anne Galer; Hendrik-Tobias Arkenau; Andrew Farnsworth; Jonathan Wilde; Jayantha Ratnayake; Donal Landers

European Journal of Cancer | 2015

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Jonathan E. Rosenberg; Daniel P. Petrylak; Oyewale O. Abidoye; M. Van Der Heijden; J. Hofman-Censits; Andrea Necchi; Peter H. O'Donnell; A. Balmanoukian; Y. Loriot; M. Retz; Jose Luis Perez-Gracia; Nancy A. Dawson; Arjun Vasant Balar; Matthew D. Galsky; Mark T. Fleming; T. Powles; Na Cui; Sanjeev Mariathasan; Gregg Fine; Robert Dreicer

Annals of Oncology | 2017

862PTreatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective

A. Gomez de Liano Lista; Andrea Necchi; P. Lavaud; J. Carles Galceran; Daniel Castellano; Alain Ravaud; Ignacio Duran; N. van Dijk; P. Giannatempo; Y. Loriot; R. Morales Barrera; G. De Velasco Oria De Rueda; F. Lefort; G. Martínez Bernal; D. Raggi; M. Gross-Goupil; T. Powles; M. Van Der Heijden

Annals of Oncology | 2017

857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Petros Grivas; Elizabeth R. Plimack; Arjun Vasant Balar; Daniel Castellano; Peter H. O'Donnell; Joaquim Bellmunt; T. Powles; Noah M. Hahn; R. de Wit; Dean F. Bajorin; M.C. Ellison; Tara L. Frenkl; Stephen Michael Keefe; Jacqueline Vuky

Explore More